title: Riociguat for pulmonary hypertension.
abstract: Riociguat is newly approved by the FDA for treatment of patients with groups 1 or 4 pulmonary hypertension. Although several vasodilators are on the market for the treatment of pulmonary hypertension group 1, none have been shown to be invariably effective in the treatment of chronic thromboembolic pulmonary hypertension.
authors.affiliation: David Pitonzo is director of didactic education and an associate professor in the PA program at High Point (N.C.) University. Mark E. Archambault is director of research and an associate professor in the PA program at High Point University and editor of this department. The authors have disclosed no potential conflicts of interest, financial or otherwise.
authors.forename: David
authors.initials: D
authors.lastname: Pitonzo
authors.forename: Mark E
authors.initials: ME
authors.lastname: Archambault
mesh_terms: D002908:Chronic Disease; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D011720:Pyrazoles / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*
chemical_list: D011720:Pyrazoles; D011743:Pyrimidines; C542595:riociguat